CClinicalTrials.gg
WithdrawnNCT03278639ERA-EP2Updated Sep 21, 2021

Efficacy and Safety or Rhythmic Auditory Stimulation (RAS) for Gait and Balance Disorders in Parkinson's Disease

An interventional study of Rhythmic Auditory Stimulation and Kinesiology in Parkinson Disease, sponsored by Pontifical Catholic University of Argentina. Withdrawn. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-09-21.

Sponsored by Pontifical Catholic University of Argentina · Not applicable, Interventional, and Treatment

Why this study was withdrawn
We could not fund the study
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
60 Years to 85 Years
Sex
All
01

Study summary

Gait deficits are among the most characteristic and most functionally debilitating signs of the motor neuropathology of Parkinson's disease (PD). Rhythmic Auditory Stimulation (RAS) is a technique by which a series of auditory stimuli are presented at a fixed rhythm, so that patients have to synchronize their movements to the rhythms. In this study, auditory stimuli will be constituted by Tango musical pieces, which tempo is modified to adapt to patients' walking cadence. Previous results suggested that RAS can increase Tinetti's gait and balance and may also improve Health-Related Quality of Life. This will be a randomized, blind, controlled clinical trial to further assess RAS efficacy and safety.

02

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • gait disorders
  • balance disorders
  • music
  • tango
  • rhythmic auditory stimulation
  • health-related quality of life
03

Who can participate

Ages eligible
60 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Clinically definitive or probable PD diagnosis
  • Gait disorders (MDS-UPDRS #2.12 =1)
  • Patients that can be reasonably expected to remain in ON-state during training sessions.

Exclusion criteria

Exclusion Criteria:

  • Previous use of RAS or kinesiology
  • MMSE >= 24
  • BDI >= 17
  • Patients having undergone PD surgical treatments.
  • Patients with auditory or visual handicaps
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Rhythmic auditory stimulation

    Each patient will receive training for 4 weeks, 3 times per week. Each training session will last 30 minutes. Training will be performed by music therapists board-certified in RAS.

    Behavioral: Rhythmic Auditory Stimulation

  • Active comparator
    Kinesiology

    Each patient will receive training for 4 weeks, 3 times per week. Each training session will last 30 minutes. Training will be performed by board-certified kinesio therapists. The objectives of the training sessions will match those of RAS.

    Behavioral: Kinesiology

Interventions

  • BehavioralRhythmic Auditory Stimulation

    Training will be directed to ameliorate gait and balance

  • BehavioralKinesiology

    Training will be directed to ameliorate gait and balance

05

What researchers measure

Primary outcomes

  1. change from baseline in Tinetti scale total score

    Time frame: 4 weeks

Secondary outcomes

  1. change from baseline in Tinetti scale Gait score

    Time frame: 4 weeks

  2. change from baseline in Tinetti scale Balance score

    Time frame: 4 weeks

  3. change from baseline in Tinetti scale total score

    training will last for the first 4 weeks. Assessments will be also performed at Month 6 to check lasting effects.

    Time frame: 6 months

  4. change from baseline in Timed Up & Go test (TUG)

    Time frame: 4 weeks

  5. change from baseline in PDQ-39 scores

    PDQ-39 is a PD-specific scale for Health-related Quality of Life

    Time frame: 4 weeks

  6. change from baseline in MDS-UPDRS score

    MDS-UPDRS is a measure of disease severity

    Time frame: 4 weeks

  7. change from baseline in Beck Depression Index (BDI)

    Time frame: 4 weeks

  8. change from baseline in MMSE (Mini-Mental State Examination)

    MMSE is a measure of cognitive impairment

    Time frame: 4 weeks

  9. change from baseline in Fall diary

    patients will have to indicate the number of daily falls over a 15-d period

    Time frame: 4 weeks

Other outcomes

  1. change from baseline in PD CRS

    Parkinson's Disease Cognitive Rating Scale (PD CRS) measures cognitive performance

    Time frame: 4 weeks and 6 months

  2. change from baseline in DRS

    Dementia Rating Scale (DRS) measures cognitive performance

    Time frame: 4 weeks and 6 months

  3. change from baseline in TUG

    Time frame: 6 months

  4. change from baseline in PDQ-39

    Time frame: 6 months

  5. change from baseline in MDS-UPDRS

    Time frame: 6 months

  6. change from baseline in BDI

    Time frame: 6 months

  7. change from baseline in MMSE

    Time frame: 6 months

  8. change from baseline in fall diary

    Time frame: 6 months

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03278639
Lead sponsor
Pontifical Catholic University of Argentina
Collaborators
National Council of Scientific and Technical Research, Argentina, Hospital Nacional Profesor Alejandro Posadas, University of Buenos Aires
Responsible party
Santiago Perez Lloret (MD PhD CPI, Pontifical Catholic University of Argentina) — Principal investigator
First posted
Sep 11, 2017
Start date
Mar 2021 (estimated)
Primary completion
Mar 2023 (estimated)
Completion
Mar 2023 (estimated)
Last update
Sep 21, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion